Miscellaneous ocular agents:

Indications for: SYFOVRE

Treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Adult Dosage:

See full labeling. Each vial is for use in a single eye. Give by intravitreal inj to each affected eye. 15mg (0.1mL of 150mg/mL solution) once every 25 to 60 days. 

Children Dosage:

Not established.

SYFOVRE Contraindications:

Ocular or periocular infection. Active intraocular inflammation.

SYFOVRE Warnings/Precautions:

Must be administered by a qualified physician. Monitor for elevated IOP prior to initiation and following inj (may give ocular hypotensive meds if needed). Monitor for endophthalmitis, retinal detachments, neovascular AMD, and perfusion of the optic nerve head following inj. Risk for intraocular inflammation; may resume after resolution. Advise females of reproductive potential to use effective contraception during and for 40 days after the last dose. Pregnancy. Nursing mothers.

SYFOVRE Classification:

Complement inhibitor.

SYFOVRE Interactions:

If anti-VEGF is required, give separately from Syfovre administration.

Adverse Reactions:

Ocular discomfort, neovascular age-related macular degeneration, vitreous floaters, conjunctival hemorrhage; intraocular inflammation.


Metabolized into small peptides and amino acids by catabolic pathways. 

Drug Elimination:

Estimated geometric mean (%CV) of clearance (CL): 0.284 L/day (21.1%). Geometric mean half-life: 4.5 days (21.1%).

Generic Drug Availability:


How Supplied:

Single-dose vial—1